Company / Shareholders' Equity
Atara Biotherapeutics, Inc. Shareholders' Equity History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$38.5M
FY2025
5-year range
-$99.2M / -$38.5M
FY2024-FY2025
Trend
+61.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Atara Biotherapeutics, Inc. reports negative total equity of -$39M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$39M in FY2025.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity increased 61.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score -73.54 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$38.5M | +61.2% |
| FY2024 | -$99.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026